COMP <GO>
LFVN vs COYA // ALTMAN Z-SCORE & DEBT/EQUITY
Lifevantage Corporation (Delaware) (NASDAQ) VS. Coya Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: LFVN 7
— COYA 3
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: COYA
LAST: $5.87 (-0.17%) • MKT CAP: $73.9M
balance-sheet
3.98
LAST: $3.23 (-10.53%) • MKT CAP: $75.8M
balance-sheet
6.08
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LFVN VS. COYA)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LFVN | COYA | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 80.40% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 29.20% | -35.00% | +64.20 | LFVN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 5.5x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 14.22% | -11.50% | +25.72 | LFVN | /fcf-yield <GO> |
| Operating Margin | 5.30% | -60.00% | +65.30 | LFVN | /operating-margins <GO> |
| Net Profit Margin | 4.30% | -60.00% | +64.30 | LFVN | /net-margins <GO> |
| Revenue Growth (YoY) | 14.20% | 123.60% | -109.40 | COYA | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 2.80% | 0.00% | +2.80 | LFVN | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 3.98 | 6.08 | -2.10 | COYA | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 3/9 | +5.00 | LFVN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 22.0 | +21.20 | LFVN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 6.3x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $73.9M | $75.8M | -$1.9M | COYA | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LFVN REV | COYA REV | LFVN GROSS % | COYA GROSS % | LFVN FCF | COYA FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $228.5M | $7.9M | 80.4% | — | $10.5M | -$10.7M |
| FY 2024 | $200.2M | $3.6M | 79.3% | — | $10.0M | -$10.3M |
| FY 2023 | $213.4M | $6.0M | — | — | $6.8M | -$11.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LFVN // BETA —
COYA // BETA —